China NT Pharma Group Co., Ltd. (HK:1011)
:1011
Want to see HK:1011 full AI Analyst Report?
Top Page
China NT Pharma Group Co., Ltd.
(1011)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$0.61
▼(-26.90% Downside)
Action:Reiterated
Date:05/12/26
The score is driven primarily by weak financial performance—ongoing heavy losses, negative equity, high leverage, and renewed cash burn. Technicals add pressure with a downtrend across key moving averages and a negative MACD. Valuation is only a minor offset because the negative P/E reflects losses and no dividend yield data is available.
Positive Factors
CNS specialty focus
A narrow therapeutic focus on CNS specialty drugs provides durable strategic clarity and higher entry barriers versus commodity generics. Specialized R&D and commercial know-how can support differentiated products, pricing power in niche markets, and more predictable regulatory pathways over months.
Negative Factors
Negative shareholders' equity
Negative equity reflects cumulative losses and materially weakens the capital structure. This elevates insolvency and refinancing risk, reduces strategic flexibility for R&D or M&A, and can limit access to conventional financing, pressuring durability of operations over months.
Read all positive and negative factors
Positive Factors
Negative Factors
CNS specialty focus
A narrow therapeutic focus on CNS specialty drugs provides durable strategic clarity and higher entry barriers versus commodity generics. Specialized R&D and commercial know-how can support differentiated products, pricing power in niche markets, and more predictable regulatory pathways over months.
Read all positive factors
China NT Pharma Group Co., Ltd. (1011) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$578.89M
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth-36.32%
EPS Growth78.17%
CountryHK
Employees22
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.04
Shares Outstanding948,997,700
10 Day Avg. Volume1,250,790
30 Day Avg. Volume1,683,352
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-1.66
Price to Sales (P/S)18.81
P/FCF Ratio-18.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China NT Pharma Group Co., Ltd. Business Overview & Revenue Model
Company Description
China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical products in the People's Republic of China and internationally. It manufacture...
How the Company Makes Money
null...
China NT Pharma Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
9
Very Negative
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 24.16M | 37.96M | 7.37M | 207.09M | 226.70M |
| Gross Profit | 9.61M | 5.26M | 7.37M | 125.29M | 145.46M |
| EBITDA | -12.32M | -8.65M | 1.33M | 10.39M | -17.78M |
| Net Income | -26.04M | -53.36M | -143.59M | -66.41M | -149.54M |
Balance Sheet | |||||
| Total Assets | 347.50M | 334.07M | 329.12M | 1.01B | 955.36M |
| Cash, Cash Equivalents and Short-Term Investments | 7.22M | 9.62M | 1.52M | 5.93M | 9.44M |
| Total Debt | 316.83M | 375.95M | 344.94M | 826.45M | 832.11M |
| Total Liabilities | 621.45M | 733.18M | 668.69M | 1.25B | 1.17B |
| Stockholders Equity | -273.74M | -399.11M | -339.56M | -241.66M | -211.38M |
Cash Flow | |||||
| Free Cash Flow | -24.71M | -9.24M | 37.58M | 31.72M | -135.42M |
| Operating Cash Flow | -24.55M | -9.07M | 50.48M | 36.21M | -134.78M |
| Investing Cash Flow | -154.88K | -189.00K | -22.14M | 4.53M | 257.81M |
| Financing Cash Flow | 24.05M | 12.65M | -28.97M | -46.68M | -124.80M |
China NT Pharma Group Co., Ltd. Technical Analysis
Negative
0.84
Price Trends
0.68
Negative
0.74
Negative
0.81
Negative
Market Momentum
-0.02
Positive
41.68
Neutral
18.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1011, the sentiment is Negative. The current price of 0.84 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.68, and above the 200-day MA of 0.81, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.68 is Neutral, neither overbought nor oversold. The STOCH value of 18.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1011.
China NT Pharma Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | HK$772.87M | 3.58 | 12.80% | 7.52% | -9.66% | 16.17% | |
81 Outperform | HK$6.41B | 6.14 | 11.90% | 5.80% | -17.03% | 12.82% | |
72 Outperform | HK$1.70B | 7.83 | 6.34% | 5.16% | 16.09% | -62.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$356.60M | 43.65 | -1.17% | 7.50% | 59.60% | -351.02% | |
45 Neutral | HK$160.48M | -4.22 | -30.35% | ― | -12.03% | 6.24% | |
42 Neutral | HK$578.89M | -17.45 | 9.46% | ― | -36.32% | 78.17% |
* Healthcare Sector Average
HK:1011
China NT Pharma Group Co., Ltd.
0.61
0.17
38.64%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.32
-0.03
-8.57%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.21
-41.18%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.13
0.03
2.73%
HK:0239
Pak Fah Yeow International Limited
2.48
0.23
10.22%
HK:2877
China Shineway Pharmaceutical Group Limited
8.48
1.53
21.98%
China NT Pharma Group Co., Ltd. Corporate Events
China NT Pharma details board and committee structure
May 12, 2026
China NT Pharma Group Co., Ltd., a Cayman Islands–incorporated pharmaceutical company listed in Hong Kong under stock code 1011, has outlined the composition of its board of directors, including executive, non-executive and independent non-e...
China NT Pharma Reveals Past Unannounced Connected Transactions and Compliance Lapses
May 8, 2026
China NT Pharma has disclosed that past financing arrangements involving share pledges and loan agreements with connected parties were not properly treated as notifiable and connected transactions under Hong Kong listing rules. The company’s...
China NT Pharma Reshapes Audit Oversight with New Independent Director
May 8, 2026
China NT Pharma Group has appointed Mr. Kwok Che Chung as an independent non-executive director and chairman of its audit committee, effective 8 May 2026, for a three-year term with annual remuneration of HKD150,000. Kwok brings around 17 years of...
China NT Pharma Advances AI Health Pivot as It Negotiates Debt Restructuring
Apr 30, 2026
China NT Pharma Group has completed a major acquisition, taking indirect control of 58.11% of Zhejiang Kangyuan Medical Device and integrating its AI X-ray bone density systems, portable AI X-ray devices, patents, and source codes into the group&#...
China NT Pharma Calls 2026 AGM, Seeks Renewal of Share Issuance Mandate
Apr 30, 2026
China NT Pharma Group Company Limited has convened its annual general meeting for 4 June 2026 in Hong Kong to review and adopt the audited consolidated financial statements and directors’ and auditors’ reports for the financial year en...
China NT Pharma Names Major Shareholder Lou Yongbin as Non-Executive Director to Support AI Healthcare Pivot
Apr 13, 2026
China NT Pharma Group has appointed entrepreneur and investor Lou Yongbin as a non-executive director effective 13 April 2026, as the company deepens its push into medical technology and AI healthcare. Lou, who chairs Zhejiang Kangyuan Medical Dev...
China NT Pharma Narrows Annual Loss Despite Revenue Decline in 2025
Mar 31, 2026
China NT Pharma Group reported audited annual results for the year ended 31 December 2025, showing revenue of RMB24.16 million, down from RMB37.96 million a year earlier, but an improved gross profit of RMB9.61 million versus RMB5.26 million in 20...
China NT Pharma Narrows Expected 2025 Loss on One-Off Debt-Settlement Gain
Mar 30, 2026
China NT Pharma Group said it expects to book a one-off, non-cash gain of about HK$15.4 million from issuing new shares to settle debt, following discussions with its auditor during the 2025 year-end audit. As a result, the group’s previousl...
China NT Pharma Completes Share-Financed Acquisition and Reshapes Shareholding Structure
Mar 25, 2026
China NT Pharma Group Company Limited has completed a major transaction to acquire 100% of the issued shares in three target companies, paying the consideration by issuing 274,751,679 new shares at HK$0.45 each to eight sellers. As a result, these...
China NT Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 18, 2026
China NT Pharma Group Company Limited, a Cayman Islands-incorporated pharmaceutical group listed on the Hong Kong Stock Exchange (stock code 1011), has a board structure that includes executive, non-executive, and independent non-executive directo...
China NT Pharma Flags Sharply Narrower 2025 Loss Driven by Fair Value Gains
Feb 26, 2026
China NT Pharma Group has warned shareholders and investors that it expects to remain loss-making for the year ended 31 December 2025, but forecasts a sharply narrower net loss of about RMB25 million to RMB30 million. This represents a reduction o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.